Introduction. Patients with interstitial lung disease (ILD) who subsequently develop a viral infection have high rates of morbidity and mortality. Hypothesis/Gap Statement. Few large- scale epidemiological studies have investigated potential prognostic factors for mor-bidity and mortality in this patient group. Aim. To evaluate the risk factors for morbidity and mortality in hospitalized patients with ILD and viral infection, as well as the clinical characteristics. Methodology. This retrospective cohort study included patients with ILD who were hospitalized for a viral infection in two ter-tiary academic hospitals in China, between 1 January 2013 and 31 December 2019. We analysed the prevalence of comorbidi-ties, clinical characteristics, 30 day mortality rates, and prognostic risk factors. Results. A total of 282 patients were included; 195 and 87 were immunocompromised and immunocompetent, respec-tively. The most common underlying interstitial diseases were idiopathic pulmonary fibrosis (42.9 %) and connective tissue disease (36.9 %). The 30 day mortality rate was 20.6 %. During the influenza season, an increase in influenza virus (IFV) (25.7 %), respiratory syncytial virus (14.9 %) and cytomegalovirus (CMV) (11.3 %) cases was observed in the immunocompro-mised group. The most frequently detected virus in the immunocompetent group was IFV (44.8 %), followed by respiratory syncytial virus (11.5 %), and human rhinovirus (9.2 %). During the non- influenza season, CMV (34.4 %) was the main virus detected in the immunocompromised group. The 30 day mortality rates of non- IFV patients were higher than those of IFV patients. Older age (>60 years), respiratory failure, persistent lymphocytopenia, invasive mechanical ventilation and non-IFV virus infection were significantly associated with increased 30 day mortality. Conclusion. Patients with ILD who develop viral infection have high rates of morbidity and mortality, which are associated with increased age (>60 years), respiratory failure, mechanical ventilation, persistent lymphocytopenia and non- IFV virus infection. These risk factors should be carefully considered when determining treatment strategies for this patient population.